Fresh off $7.5M funding, this new-to-Houston tech company plans to grow and expand in life science space

q&A

Alex Reed, co-founder and CEO of Fluence Analytics, joined InnovationMap for a Q&A on the company's move to Houston and its growth plans. Photo courtesy of Fluence Analytics

Founded in 2012 in New Orleans, a tech company that provides software and hardware solutions for the chemicals industry has entered its next phase of growth by moving its headquarters to Houston following a $7.5 million venture capital raise

Fluence Analytics, which announced its recent raise led by Yokogawa Electric Corp. last month, has officially moved to the Houston area. The company's new HQ is in Stafford. Alex Reed, co-founder and CEO of the company, joined InnovationMap for a Q&A about what led up to the move and the future of the company, which includes expanding into the life science field.

InnovationMap: Tell me about Fluence Analytics — what does the technology do and why did you decide to start the company?

Alex Reed: We have developed a patented technology that can optimize chemical production. We basically are able to measure what's happening in real time in a process. Imagine if you're baking a cake, and you follow this recipe and sometimes you get the cake you want, sometimes it's too dry, and sometimes it's not cooked enough. And so the polymers industry, for simplistic terms, has that type of an issue. You don't really know exactly where you're at your equipment behaves differently. Basically, what we're able to do is give them real-time information on what's happening as they're baking the cake so that every time they can get a perfect cake.

We have a software and hardware solution that we install in these plants to get these measurements so that our customers can optimize production — and they want to do that to improve their yield, reduce waste, increase safety, and improve quality. There are a lot of different reasons that companies are interested in our technology and we have managed to grow globally. We have customers in Asia, Europe, and the U.S.

We spun out of Tulane University. It's an interesting story because my dad is the inventor of the technology — he's a physics professor at Tulane. I grew up working in the lab with him literally since the age of 12, and I was super interested in technology and science and saw that he was working with all these chemical companies. They were always very interested in what he was working on. I got to the point where I realized that I didn't want to be a scientist — I was far more interested in the commercialization and how you go from lab to product. That transition is very difficult. So, I stepped into the role of the entrepreneur. We had the patents and technology for my dad, I had an excellent mentor, and then our other co-founder was a technical founder.

IM: When and why did you start considering an HQ move? 

AR: We raised our first institutional venture funding in April 2017. Up until that point, it was primarily working with customers and grant funding. We worked with actually a group that has an office here called Energy Innovation Capital. They came in and invested in us and supported us, and George Coyle joined our board.

So, we had that tie to Houston, and I was in Houston a lot because there was a concentration of partners and customers — and not just like chemical plant customers, but also technology and R&D centers. As we started to scale, we brought on some other investors — Mitsubishi Chemical, JSR Corp., and most recently Yokogawa Electric Corp., which has its North American headquarters in Sugar Land.

We started to just build momentum towards it. I'd say we first had the conversations pre-COVID and then COVID hit, and we'd kind of just stopped everything for a while, just to make sure we knew where the business was heading. We've made it through COVID fine and did well on coming out of it. Then we felt it was the right time to pick that thread back up. We knew it made sense. The labor pool is amazing here, and there's just so many reasons why we were looking at it. So then we just pulled the trigger.

IM: How did you decide on the Houston area? What drew you to Stafford?

AR: Initially, we had a little landing pad in the East End Maker Hub, so we got in there and they were awesome. We actually had started hiring remote people here in 2019 because we knew the move was going to happen at some point. We had a place for them to go work out of EEMH while we searched for a permanent facility. We connected with the Greater Houston Partnership, and they plugged us in to Houston Exponential, and they have been very good at introducing us to the right people. We just don't know the lay of the land to be honest, so they've been a great resource. We were looking originally on the northside of Houston, and then we saw the Stafford area. There's a huge concentration of similar type companies — automation, some software, some hardware. There were some tax advantages. We settled in the Stafford area and are very happy with the choice we made to end up here.

IM: I know you recently raised a $7.5M venture funding round. What does that funding mean for growth?

AR: Like any capital, the objective is to use it to grow. For us, "grow" has several different areas. One is the product. There's a very long roadmap of both hardware and software improvements that we want to make. So basically we're accelerating a lot of the things on our roadmap to do things like closed-loop control based on our data — imagine running a whole plant autonomously based on measurements that we're making. We're moving more and more toward that autonomous operation world and improving a lot of the actual underlying hardware, making the measurements, building out sales and marketing as we start to serve more and more customers. Product sales and marketing and customer success are the areas that we're scaling.

IM: As you grow your local team, what are you looking for?

AR: Field applications, software, some automation technicians, and more. We do have some life science applications. So, in addition to our core area on the chemical side, we have a product we've sold into biopharma, and so we want to grow some of that. We're actually hiring for a product manager for the life science side of the business. So, that one's a pretty unique opportunity and role.

IM: Considering your life science application, it seems like Houston is a good fit for that vertical as well, right?

AR: We're working with the Houston of today, but also the Houston of tomorrow, which is this life science play. The next phase is kind of following that innovation value chain. So, figuring out what's the R&D and manufacturing of these pharmaceuticals, and how you can attract more of those technology centers and factories to make the stuff here. If you look at the talent pool here, those resources are somewhat fungible with the resources that serve petrochemical and oil and gas.

This cross pollination I think actually could be quite an interesting differentiator for Houston if the city can build that critical mass. So yes, I think there is an opportunity for us to leverage this vision that Houston has for life science. Now, we'll still have to go to the coast to go to our customers, but I think talent pool, and eventually you might even have customers here. It's certainly feasible.

------

This conversation has been edited for brevity and clarity.
Solugen closed its Series C funding round at $357 million to grow its chemical products. Photo via Getty Images

Houston chemicals company raises $357M, claims unicorn status

money moves

Houston-based Solugen, a startup that specializes in combating carbon dioxide emitted during the production of chemicals, has hauled in $357 million in a Series C funding round. That amount eclipses the size of any Houston VC funding round this year or last year.

The Series C round lifts Solugen's pre-money valuation to $1.5 billion, according to the Axios news website. This gives Solugen "unicorn" status as a startup with a valuation of at least $1 billion.

Singapore-based GIC and Edinburgh, Scotland-based Baillie Gifford led the round, with participation from Temasek Holdings, affiliates of BlackRock, Carbon Direct Capital Management, Refactor Capital, and Fifty Years.

Since its founding in 2016, Solugen has raised more than $405 million in venture capital, according to Crunchbase.

"Solugen's vision for cleaner chemicals through synthetic biology has the potential to be a fundamental shift in how chemicals are made, to help tackle the environmental challenges we face globally. The chemical market itself is colossal, and Solugen is just getting started," Kirsty Gibson, investment manager at Baillie Gifford, says in a September 9 news release.

Solugen's patented Bioforge processes produce "green" chemicals from bio-based feedstocks. These chemicals are aimed at reducing or eliminating carbon emissions from chemical producers. The Series C funding will help Solugen expand the Bioforge platform and broaden the reach of Solugen's products.

Carbon dioxide from chemical production ranks among the greatest contributors to industrial greenhouse gas emissions.

CNBC explains that Solugen designs and grows enzymes that can turn sugar into chemicals needed to make an array products used in many industrial settings. The company's bio-based chemical offering already includes water treatments, a chemical that makes concrete stronger, another chemical that makes fertilizers more efficient, and detergents that are strong enough to clean a locker room or mild enough to be used for facial wipes, according to CNBC.

"This fundraising round allows us to continue expanding the footprint of our Bioforge technology to give industries the products they need to reduce emissions in their existing supply chains, without compromising on performance or economics," Sean Hunt, co-founder and chief technology officer of Solugen, says in the news release.

Three days before the funding announcement, Solugen made news of a different sort.

Axios reported September 7 that Solugen plans to open a new R&D facility outside Texas because many of the state's social policies — including its abortion restrictions — are making it hard to recruit employees.

Solugen employs about 115 people, most of whom work from its Houston headquarters, Axios says. The startup plans to more than double its R&D capability over the next two years, representing around 100 jobs, with most of those workers expected to be assigned to a new facility that will be set up in California or Massachusetts.

"We want to make sure we're hiring the top enzymologists and chemical engineers," Solugen CEO Gaurab Chakrabarti tells Axios. "We've come to the conclusion after talking to lots of candidates that they want to join Solugen, but they don't feel comfortable coming to Texas, so for us it's become a no-brainer to have R&D facilities elsewhere."
Solugen, which uses plant-centered biotechnology to produce environmentally friendly chemicals, has raised an additional $30 million and is speculated to soon reach unicorn status. Photo via solugentech.com

Houston startup raises $30M, plans to be 'next iconic chemical company' with plant-based alternatives

climate tech

While Forbes recently anointed Houston-based Solugen Inc. as one of the next billion-dollar "unicorns" in the startup world, Dr. Gaurab Chakrabarti shrugs off the unicorn buzz.

Chakrabarti, a physician and scientist who's co-founder and CEO of the startup, concedes he doesn't know whether Solugen will be worth $1 billion or not. But he does know that the startup aspires to be a key competitor in the emerging "climate tech" sector, whose players strive to combat climate change. Chakrabarti estimates the climate-tech chemical space alone represents a global market opportunity valued at $1 trillion to $2 trillion per year.

Solugen's overarching goal in the climate-tech market: Replace petroleum-based chemicals with plant-based substitutes.

"I'd love it if we were the poster child that drives climate tech to be the next big, sexy trend," Chakrabarti says.

Chakrabarti acknowledges Solugen's investors, executives, and employees hope the startup succeeds financially. But success, he believes, goes beyond making money and plotting an exit strategy. Instead, Chakrabarti emphasizes "a shift in thinking" on climate tech that he says promises to transform the fledgling sector into a "true niche" that'll be "good for everyone."

"Who cares if people are all hyped up for the wrong reasons?" says Chakrabarti, referring to the unicorn speculation.

Solugen sits at the crossroads of biology and chemistry. In short, the startup taps into plant-centered biotechnology to produce environmentally friendly chemicals and "decarbonize" the chemical industry.

"Quite simply, we want to become the next DowDuPont or the next iconic chemical company, but using principles of green chemistry instead of principles from petroleum chemistry," Chakrabarti says.

If Solugen does reach the icon stratosphere, Chakrabarti envisions it doing so on a speedy schedule. In the traditional petrochemical market, it can take 10 to 20 years to put a new product on the market, he says. "I don't have that kind of time. I'm a very impatient person," Chakrabarti says.

Gaurab Chakrabarti Gaurab Chakrabarti, CEO and co-founder of Solugen, isn't paying any mind to his company's predicted unicorn status — rather he's focusing on the difference he can make on reducing carbon emissions. Photo via solugentech.com

Spurred by that restlessness, Chakrabarti seeks to propel Solugen's products from concept to commercialization in the span of two years. He says the startup already has proven the ability to do that with its sugar-derived hydrogen peroxide product.

"We're going to continue to do that, and it would be great if we can continue demonstrating new [products] coming to market once a year," says Chakrabarti, who grew up in Sugar Land.

Solugen seems to have plenty of financial fuel to make that happen. In April, Solugen raised $30 million in venture capital as an add-on to its Series B funding, which initially closed May 2019. That brings its total VC haul to $68 million since it was founded in 2016, according to Forbes. The recent funding lifted the company's valuation to $250 million, putting it $750 million away from unicorn territory.

Chakrabarti doesn't dismiss the notion of an eventual IPO for Solugen but says being acquired isn't "terribly interesting to me."

"If you want to make money, you can always go be a banker," he notes.

Chakrabarti estimates Solugen will generate $30 million to $40 million in revenue this year, up from $12 million in 2019. Profit remains elusive, though, as the company pours its gains into R&D. The company graduated in 2017 from the Y Combinator startup accelerator. Aside from Y Combinator and Unicorn Venture Partners, investors include Founders Fund, Refactor Capital, Fifty Years, and KdT Ventures.

Solugen's current lineup features fewer than a half-dozen products, which are sold to industrial and government customers. Hundreds more products are in the pipeline for use in sectors like agriculture and energy, Chakrabarti says.

"It's one of the blessings and curses of this company — there's always something to work on, always something big to scale up," says Chakrabarti, who earned his M.D. and Ph.D. from the University of Texas Southwestern Medical Center in Dallas.

Working on selling Solugen's current products and developing its new products are 70 employees, located at its headquarters in Houston and its new production facility in Lubbock. By the end of this year, the startup should employ close to 100 people, Chakrabarti says.

Chakrabarti hesitates to identify Solugen's competitors, as he believes a perceived rival very well could end up becoming a partner.

"I think everyone eventually should be a partner of Solugen, not competition," he says. "It's an ideology that's actually the competition, an ideology like, 'We've always used petrochemistry. This is just how it's been done.'"
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-based health tech startup is revolutionizing patient selection for clinical trials

working smarter

On many occasions in her early career, Dr. Arti Bhosale, co-founder and CEO of Sieve Health, found herself frustrated with having to manually sift through thousands of digital files.

The documents, each containing the medical records of a patient seeking advanced treatment through a clinical trial, were always there to review — and there were always more to read.

Despite the tediousness of prescreening, which could take years, the idea of missing a patient and not giving them the opportunity to go through a potentially life-altering trial is what kept her going. The one she didn’t read could have slipped through the cracks and potentially not given someone care they needed.

“Those stories have stayed with me,” she says. “That’s why we developed Sieve.”

When standard health care is not an option, advances in medical treatment could be offered through clinical trials. But matching patients to those trials is one of the longest standing problems in the health care industry. Now with the use of new technology as of 2018, the solution to the bottleneck may be a new automated approach.

“Across the globe, more than 30 percent of clinical trials shut down as a result of not enrolling enough patients,” says Bhosale. “The remaining 80 percent never end up reaching their target enrollment and are shut down by the FDA.”

In 2020, Bhosale and her team developed Sieve Health, an AI cloud-based SaaS platform designed to automate and accelerate matching patients with clinical trials and increase access to clinical trials.

Sieve’s main goal is to reduce the administrative burden involved in matching enrollments, which in turn will accelerate the trial execution. They provide the matching for physicians, study sponsors and research sites to enhance operations for faster enrollment of the trials.

The technology mimics but automates the traditional enrollment process — reading medical notes and reviewing in the same way a human would.

“I would have loved to use something like this when I was on the front lines,” Bhosale says, who worked in clinical research for over 12 years. “Can you imagine going through 10,000 records manually? Some of the bigger hospitals have upwards of 100,000 records and you still have to manually review those charts to make sure that the patient is eligible for the trial. That process is called prescreening. It is painful.”

Because physicians wear many hats and have many clinical efforts on their plates, research tends to fall to the bottom of the to-do list. Finding 10-20 patients can take the research team on average 15-20 months to find those people — five of which end up unenrolling, she says.

“We have designed the platform so that the magic can happen in the background, and it allows the physician and research team to get a jumpstart,” she says.” They don’t have to worry about reviewing 10,000 records — they know what their efforts are going to be and will ensure that the entire database has been scanned.”

With Sieve, the team was able to help some commercial pilot programs have a curated data pool for their trials – cutting the administrative burden and time spent searching to less than a week.

Sieve is in early-stage start up mode and the commercial platform has been rolled out. Currently, the team is conducting commercial projects with different research sites and hospitals.

“Our focus now is seeing how many providers we can connect into this,” she says. “There’s a bigger pool out there who want to participate in research but don’t know where to start. That’s where Sieve is stepping in and enabling them to do this — partnering with those and other groups in the ecosystem to bring trials to wherever the physicians and the patients are.”

Arti Bhosale is the co-founder and CEO of Sieve Health. Photo courtesy of Sieve

Houston nonprofit unveils new and improved bayou cleaning vessel

litter free

For over 20 years, a nonprofit organization has hired people to clean 14 miles of bayou in Houston. And with a newly updated innovative boat, keeping Buffalo Bayou clean just got a lot more efficient.

Buffalo Bayou Partnership unveils its newest version of the Bayou-Vac this week, and it's expected to be fully operational this month. BBP Board Member Mike Garver designed both the initial model of the custom-designed and fabricated boat as well as the 2022 version. BBP's Clean & Green team — using Garver's boat — has removed around 2,000 cubic yards of trash annually, which is the equivalent of about 167 commercial dump trucks. The new and improved version is expected to make an even bigger impact.

“The Bayou-Vac is a game changer for our program,” says BBP field operations manager, Robby Robinson, in a news release. “Once up and running, we foresee being able to gain an entire workday worth of time for every offload, making us twice as efficient at clearing trash from the bayou.”

Keeping the bayou clean is important, since the water — and whatever trash its carrying — runs off into Galveston Bay, and ultimately, the Gulf of Mexico. The improvements made to the Bayou-Vac include removable dumpsters that can be easily swapped out, slid off, and attached to a dump truck. The older model included workers having to manually handle trash and debris and a secondary, land-based vacuum used to suck out the trash from onboard.

Additionally, the Bayou-Vac now has a moveable, hydraulic arm attached to the bow of the vessel that can support the weight of the 16-foot vacuum hose. Again, this task was something done manually on the previous model of the Bayou-Vac.

“BBP deeply appreciates the ingenuity of our board member Mike Garver and the generosity of Sis and Hasty Johnson and the Kinder Foundation, the funders of the new Bayou-Vac,” BBP President Anne Olson says in the release. “We also thank the Harris County Flood Control District and Port Houston for their longtime support of BBP’s Clean & Green Program.”

5 most popular innovation stories in Houston this week

what's trending

Editor's note: Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included innovators to know, can't-miss August events, a guest column with workplace culture advice, and more.

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Craig Ceccanti of T-Minus Solutions, Ben Jawdat of Revterra, and Sam Sabbahi of Thermocuff. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from software development to medical devices — recently making headlines in Houston innovation. Click here to continue reading.

Growing Houston sportstech company rebrands following platform expansion

This growing mobile ordering startup has rebranded to represent its growth. Photo courtesy of sEATz

The Houston startup that enabled in-seat food and beverage ordering at stadiums has grown over the past few years — and the company has entered into its new era with a rebrand.

Houston-based sEATz expanded this year to evolve its technology to enable optimized mobile ordering within hospitals. Launching that new platform, called myEATz, led to a need for a defined parent company to account for the growing company. Rivalry Technology will be run by the same sEATz and myEATz team.

“I always knew that sEATz would grow into something special," says Rivalry Tech CEO and Co-Founder Aaron Knape in a news release. "As we continue to expand and grow, our brand has also grown with it. With sEATz holding sway over Sports and Entertainment, and the myEATz platform making rapid inroads into healthcare, business dining and leisure, the Rivalry Tech branding will help pull it all together.” Click here to continue reading.

10+ can't-miss Houston business and innovation events for August

Check out these conferences, pitch competitions, networking, and more in the month of August. Photo via Getty Images

Houstonians are transitioning into a new summer month, and the city's business community is mixing in networking and conference events with family vacations and time off. Here's a rundown of what all to throw on your calendar for August when it comes to innovation-related events. Click here to continue reading.

3 ways Houston small businesses can focus on employee advocacy

Employee advocacy isn't just something for larger companies to worry about, says this Houston expert. Photo via Getty Images

As society continues to be more socially conscious, greater strides have been made to boost initiatives that improve the world from a culture and climate perspective. This heightened sense of moral awareness made a natural progression into the business world as employees, consumers and communities hold companies to higher standards and demand accountability in various areas of business operations.

Fueled by the pandemic and “Great Resignation,” the movement quickly swept across corporate America, taking many companies by storm and laying the foundation for a new era of employee engagement. As a result, one of the most important trends emerging in the post-pandemic workplace is employee advocacy in response to specific societal events or company policies and practices. Click here to continue reading.

2 Houston organizations announce strategic appointments across finance and research

Here are two of the latest updates on new appointments from two Houston organizations. Photos courtesy

Three Houston innovators have new roles they're excited about this summer. From new academia to bitcoin, here's who's moving and shaking in Houston innovation. Click here to continue reading.

View All Listings